NVIV - インビボ・セラピュ―ティクス・ホ―ルディングス (InVivo Therapeutics Holdings Corp.) インビボ・セラピュ―ティクス・ホ―ルディングス

 NVIVのチャート


 NVIVの企業情報

symbol NVIV
会社名 InVivo Therapeutics Holdings Corp (インビボ・セラピュ―ティクス・ホ―ルディングス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 InVivo Therapeutics Holdings Corp. formerly Design Source Inc. is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company''s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.   インビボ・セラピュ―ティクス・ホ―ルディングスは、米国のバイオテクノロジ―研究会社。脊髄損傷治療のために生体適合物質技術を開発する。当社の技術は、チルドレンズ・メディカルセンタ―社とマサチュ―セッツ工科大学の下で許諾される知的所有権などを取り入れている。開発中の製品は、脊柱に埋め込む生体再吸収性ポリマ―など。   
本社所在地 One Kendall Square Suite B14402 Cambridge MA 02139 USA
代表者氏名 Ann Merrifield アンメリフィールド
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-863-5524
設立年月日 37712
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 12人
url www.invivotherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/nviv
adr_tso
EBITDA EBITDA(百万ドル) -18.45300
終値(lastsale) 2.03
時価総額(marketcap) 15759742.6
時価総額 時価総額(百万ドル) 18.62910
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -3.36090
当期純利益 当期純利益(百万ドル) -31.73700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Invivo Therapeutics Holdings Corp revenues was not reported. Net loss increased 39% to $17.7M. Higher net loss reflects Derivatives gain (loss) decrease from $795K (income) to $10.2M (expense) Interest income decrease of 29% to $77K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$9.91 to -$90.95.

 NVIVのテクニカル分析


 NVIVのニュース

   InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference  2021/03/12 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, which runs from March 17 – March 19 from 9:00 am – 5:00 pm ET. Dr. Toselli’s presentation will provi
   InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference  2021/03/05 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference. The conference is scheduled to be held March 9-10, 2021 in a virtual format. Dr. Toselli’s presentation will provide an ove
   InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine  2021/02/16 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complete six-month primary endpoint results from the company's single-arm INSPIRE 1.0 study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), titled “A study of
   InVivo Therapeutics may delivered a positive earnings surprise Stock market Insights & financial analysis  2020/12/31 16:20:00 Stock Market Daily
InVivo Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   InVivo Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2020/12/24 17:10:00 Stock Market Daily
InVivo Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference  2021/03/12 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, which runs from March 17 – March 19 from 9:00 am – 5:00 pm ET. Dr. Toselli’s presentation will provi
   InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference  2021/03/05 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference. The conference is scheduled to be held March 9-10, 2021 in a virtual format. Dr. Toselli’s presentation will provide an ove
   InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine  2021/02/16 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complete six-month primary endpoint results from the company's single-arm INSPIRE 1.0 study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), titled “A study of
   InVivo Therapeutics may delivered a positive earnings surprise Stock market Insights & financial analysis  2020/12/31 16:20:00 Stock Market Daily
InVivo Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   InVivo Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2020/12/24 17:10:00 Stock Market Daily
InVivo Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference  2021/03/12 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, which runs from March 17 – March 19 from 9:00 am – 5:00 pm ET. Dr. Toselli’s presentation will provi
   InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference  2021/03/05 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference. The conference is scheduled to be held March 9-10, 2021 in a virtual format. Dr. Toselli’s presentation will provide an ove
   InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine  2021/02/16 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complete six-month primary endpoint results from the company's single-arm INSPIRE 1.0 study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), titled “A study of
   InVivo Therapeutics may delivered a positive earnings surprise Stock market Insights & financial analysis  2020/12/31 16:20:00 Stock Market Daily
InVivo Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   InVivo Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2020/12/24 17:10:00 Stock Market Daily
InVivo Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

 関連キーワード  (先端医療機器_テクノロジ― 米国株 インビボ・セラピュ―ティクス・ホ―ルディングス NVIV InVivo Therapeutics Holdings Corp.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)